{"id":6065,"date":"2025-10-29T17:19:36","date_gmt":"2025-10-29T17:19:36","guid":{"rendered":"https:\/\/www.lyosmd.com\/blog\/?p=6065"},"modified":"2025-10-29T17:19:37","modified_gmt":"2025-10-29T17:19:37","slug":"renuvion-and-safety-understanding-the-fda-approvals-myths","status":"publish","type":"post","link":"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/","title":{"rendered":"Renuvion and Safety: Understanding the FDA Approvals &amp; Myths"},"content":{"rendered":"\n<p>At <a href=\"\/\">Lyos Plastic Surgery &amp; Dermatology Associates<\/a>, we believe that clarity and transparency are essential when it comes to emerging technologies like <a href=\"\/body\/jplasma-skin-tightening\/\">Renuvion (J-Plasma)<\/a>. As one of Houston\u2019s leading centers for advanced aesthetic surgery and non-surgical rejuvenation, we\u2019re committed to educating our patients with verified, science-based information. This article was written to explain the FDA\u2019s current approvals, clarify common misconceptions, and share how Dr. Andrew Lyos\u2019s triple-board-certified expertise ensures that every Renuvion procedure in our care is performed with the highest standards of safety and precision.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What the FDA Has Cleared, and What it Hasn\u2019t<\/h2>\n\n\n\n<p>First, let\u2019s review a crucial distinction:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The Renuvion \/ J-Plasma system has long had FDA clearance for general surgical uses like cutting, coagulation, and ablation of soft tissue in open or laparoscopic procedures (<a href=\"https:\/\/www.fda.gov\/medical-devices\/safety-communications\/update-use-renuvionj-plasma-device-certain-aesthetic-procedures-fda-safety-communication\">U.S. Food and Drug Administration<\/a>)<\/li>\n\n\n\n<li>Until recently, its use for purely aesthetic skin tightening (i.e., \u201cskin contraction\u201d or dermal resurfacing) was not FDA-cleared, and the FDA issued a warning cautioning against marketing it for those purposes (<a href=\"https:\/\/content.govdelivery.com\/accounts\/USFDA\/bulletins\/30e38a0\">GovDelivery<\/a>)<\/li>\n\n\n\n<li>In May 2023, however, the FDA granted a critical 510(k) clearance for a specific APR handpiece of Renuvion\u2014for coagulation of subcutaneous soft tissues following liposuction, to assist in improving the appearance of loose skin in the neck\/submental region<\/li>\n\n\n\n<li>That new handpiece clearance also permits coagulation of soft tissues after liposuction in other body areas (<a href=\"https:\/\/apyxmedical.com\/renuvion-receives-fda-clearance-for-specific-use-after-liposuction\/\" target=\"_blank\" rel=\"noreferrer noopener\">Apyx Medical<\/a>)<\/li>\n\n\n\n<li>The FDA\u2019s 510(k) summary document confirms that the Renuvion APR handpiece is now indicated for subcutaneous dermatological and aesthetic procedures to improve lax skin in the neck\/submental area and to coagulate soft tissues after liposuction (<a href=\"https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/K230272.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">FDA Access Data<\/a>)<\/li>\n<\/ul>\n\n\n\n<p>In short, the FDA has validated Renuvion\u2019s use in very specific settings, particularly in conjunction with liposuction, but has not granted blanket clearance for all skin-tightening applications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Common Renuvion Misconceptions &amp; Myths<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Renuvion is fully FDA-approved for tightening skin everywhere<\/strong>: Not quite. It\u2019s now cleared for certain subdermal soft-tissue contraction under limited conditions, especially post-liposuction. However, using it solely for dermal resurfacing or skin contraction outside of its cleared uses remains \u201coff-label.\u201d<\/li>\n\n\n\n<li><strong>FDA warning means it\u2019s unsafe<\/strong>: The FDA\u2019s 2022 caution targeted uses for dermal resurfacing and skin contraction because these uses had not been cleared, and some adverse events had been reported. It\u2019s not a ban but a reminder to use only within approved parameters and ensure patient safety.<\/li>\n\n\n\n<li><strong>Renuvion causes frequent major complications<\/strong>: In properly indicated uses, complication rates are low. The published IDE (Investigational Device Exemption) trial for neck\/submental laxity reported no serious device-related adverse events and high patient satisfaction. (RENUVION) Also, a retrospective safety analysis of 483 patients treated post-liposuction across multiple body areas showed no new or elevated risks compared to liposuction alone.<\/li>\n\n\n\n<li><strong>If a use is off-label, it\u2019s risky<\/strong>: Off-label does not automatically equal unsafe\u2014many devices and drugs are used off-label in established, evidence-backed ways. However, the surgeon\u2019s training, judgment, and adherence to safety protocols are especially crucial when working outside FDA-cleared settings (<a href=\"https:\/\/www.americanboardcosmeticsurgery.org\/news\/fda-releases-warning-about-renuvion\/\" target=\"_blank\" rel=\"noreferrer noopener\">FDA Releases Warning About Renuvion for Skin Tightening and Dermal Resurfacing<\/a>).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical Evidence Supporting Safety<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In the IDE clinical trial of Renuvion APR for neck \/ submental skin laxity, the device met safety endpoints, with mostly mild pain or discomfort that resolved without serious events (<a href=\"https:\/\/physicians.renuvion.com\/wp-content\/uploads\/2024\/02\/Ruff-et-al-IDE-Neck-and-Submental-2023-FOR-DISSEMINATION.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">RENUVION<\/a>)<\/li>\n\n\n\n<li>The same trial also demonstrated effectiveness, with approximately 82.5% of treated patients achieving the primary endpoint of improved laxity at 6 months<\/li>\n\n\n\n<li>The 2023 retrospective 483-patient safety analysis (1,184 body areas treated) showed that using Renuvion after liposuction did not increase complication rates compared to liposuction alone (<a href=\"https:\/\/www.businesswire.com\/news\/home\/20240122132887\/en\/Apyx-Medical-Corporation-Announces-Peer-Reviewed-Clinical-Publication-Evaluating-the-Safety-of-Renuvion-Following-Liposuction-in-Multiple-Areas-of-the-Body\" target=\"_blank\" rel=\"noreferrer noopener\">Business Wire<\/a>)<\/li>\n\n\n\n<li>Bench and ex vivo testing support the mechanism: Renuvion transfers less heat to the epidermis compared to some bulk-heating RF devices, reducing the risk of thermal injury<\/li>\n\n\n\n<li>It\u2019s important to note that while these data are promising, longer-term, prospective studies beyond 6 months, with broader body areas, are still emerging.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">How We Apply Renuvion Safely In Our Practice<\/h2>\n\n\n\n<p>Because safety depends so much on how the device is used, here\u2019s how we ensure excellent outcomes:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>We adhere to clear indications or evidence-based guidelines<\/strong>. We use Renuvion where clinical evidence supports its use\u2014especially in conjunction with liposuction or for neck\/submental laxity\u2014rather than speculative, experimental use.<\/li>\n\n\n\n<li><strong>Our surgical technique is meticulous<\/strong>. Helium plasma energy is delivered via subdermal passes through small incisions, at safe power settings, and with temperature control in mind. Dr. Lyos\u2019s experience as a triple board-certified surgeon (plastic, facial\/reconstructive, and otolaryngology) provides him with the anatomical insight to avoid vital structures.<\/li>\n\n\n\n<li><strong>Our patient selection is critical<\/strong>. Good candidates are those with mild to moderate skin laxity, adequate skin quality, and realistic expectations. Patients with very heavy laxity often need excisional surgery.<\/li>\n\n\n\n<li><strong>Comprehensive planning &amp; transparency<\/strong>. Before treatment, we review risks, benefits, alternative treatments, and prior outcomes. We ensure that patients understand what is off-label and how we are mitigating the associated risks.<\/li>\n\n\n\n<li><strong>Close postop monitoring<\/strong>. We closely follow patients for signs of complications (burns, gas collections, nerve changes) and intervene early if anything questionable arises.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">The Bottom Line: Renuvion is Safe When Expertly Performed<\/h2>\n\n\n\n<p>Renuvion (J-Plasma) represents one of the most innovative advancements in modern body contouring, but like any technology, its safety depends on expert knowledge, proper technique, and ethical application. At Lyos Plastic Surgery &amp; Dermatology Associates, we use Renuvion within evidence-based parameters and FDA-cleared indications, always prioritizing patient safety over marketing trends.<\/p>\n\n\n\n<p>Clinical research consistently demonstrates that Renuvion, when performed by a highly trained and triple-board-certified surgeon like <a href=\"\/about\/meet-dr-lyos\/\">Dr. Andrew Lyos<\/a>, yields effective and precise results with low complication rates and high patient satisfaction. Our approach is based on scientific principles, transparency, and personalized care, ensuring that you understand each step before treatment begins.<\/p>\n\n\n\n<p>If you\u2019re considering Renuvion to tighten or refine your contours, we invite you to <a href=\"\/contact\/\">schedule a private consultation<\/a> at our Houston or The Woodlands location. Together, we\u2019ll design a plan that\u2019s medically sound, beautifully tailored, and performed with the uncompromising safety standards that define our practice.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At Lyos Plastic Surgery &amp; Dermatology Associates, we believe that clarity and transparency are essential when it comes to emerging technologies like Renuvion (J-Plasma). As one of Houston\u2019s leading centers for advanced aesthetic surgery and non-surgical rejuvenation, we\u2019re committed to educating our patients with verified, science-based information. This article was written to explain the FDA\u2019s &hellip; <a href=\"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Renuvion and Safety: Understanding the FDA Approvals &amp; Myths<\/span> <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6065","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Renuvion and Safety: Understanding the FDA Approvals &amp; Myths - Dr. Andrew Lyos - Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Renuvion and Safety: Understanding the FDA Approvals &amp; Myths - Dr. Andrew Lyos - Blog\" \/>\n<meta property=\"og:description\" content=\"At Lyos Plastic Surgery &amp; Dermatology Associates, we believe that clarity and transparency are essential when it comes to emerging technologies like Renuvion (J-Plasma). As one of Houston\u2019s leading centers for advanced aesthetic surgery and non-surgical rejuvenation, we\u2019re committed to educating our patients with verified, science-based information. This article was written to explain the FDA\u2019s &hellip; Continue reading Renuvion and Safety: Understanding the FDA Approvals &amp; Myths &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/\" \/>\n<meta property=\"og:site_name\" content=\"Dr. Andrew Lyos - Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T17:19:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T17:19:37+00:00\" \/>\n<meta name=\"author\" content=\"studio3\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"studio3\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/\",\"url\":\"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/\",\"name\":\"Renuvion and Safety: Understanding the FDA Approvals &amp; Myths - Dr. Andrew Lyos - Blog\",\"isPartOf\":{\"@id\":\"https:\/\/www.lyosmd.com\/blog\/#website\"},\"datePublished\":\"2025-10-29T17:19:36+00:00\",\"dateModified\":\"2025-10-29T17:19:37+00:00\",\"author\":{\"@id\":\"https:\/\/www.lyosmd.com\/blog\/#\/schema\/person\/401fd8985cd2c1a9400ff99d1eb3e606\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lyosmd.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Renuvion and Safety: Understanding the FDA Approvals &amp; Myths\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lyosmd.com\/blog\/#website\",\"url\":\"https:\/\/www.lyosmd.com\/blog\/\",\"name\":\"Dr. Andrew Lyos - Blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lyosmd.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lyosmd.com\/blog\/#\/schema\/person\/401fd8985cd2c1a9400ff99d1eb3e606\",\"name\":\"studio3\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.lyosmd.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9c5ffeafe60563b0bf588751b0c77210cd130d78326974eaf8107bd04097d202?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9c5ffeafe60563b0bf588751b0c77210cd130d78326974eaf8107bd04097d202?s=96&d=mm&r=g\",\"caption\":\"studio3\"},\"url\":\"https:\/\/www.lyosmd.com\/blog\/author\/studio3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Renuvion and Safety: Understanding the FDA Approvals &amp; Myths - Dr. Andrew Lyos - Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/","og_locale":"en_US","og_type":"article","og_title":"Renuvion and Safety: Understanding the FDA Approvals &amp; Myths - Dr. Andrew Lyos - Blog","og_description":"At Lyos Plastic Surgery &amp; Dermatology Associates, we believe that clarity and transparency are essential when it comes to emerging technologies like Renuvion (J-Plasma). As one of Houston\u2019s leading centers for advanced aesthetic surgery and non-surgical rejuvenation, we\u2019re committed to educating our patients with verified, science-based information. This article was written to explain the FDA\u2019s &hellip; Continue reading Renuvion and Safety: Understanding the FDA Approvals &amp; Myths &rarr;","og_url":"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/","og_site_name":"Dr. Andrew Lyos - Blog","article_published_time":"2025-10-29T17:19:36+00:00","article_modified_time":"2025-10-29T17:19:37+00:00","author":"studio3","twitter_card":"summary_large_image","twitter_misc":{"Written by":"studio3","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/","url":"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/","name":"Renuvion and Safety: Understanding the FDA Approvals &amp; Myths - Dr. Andrew Lyos - Blog","isPartOf":{"@id":"https:\/\/www.lyosmd.com\/blog\/#website"},"datePublished":"2025-10-29T17:19:36+00:00","dateModified":"2025-10-29T17:19:37+00:00","author":{"@id":"https:\/\/www.lyosmd.com\/blog\/#\/schema\/person\/401fd8985cd2c1a9400ff99d1eb3e606"},"breadcrumb":{"@id":"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.lyosmd.com\/blog\/renuvion-and-safety-understanding-the-fda-approvals-myths\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lyosmd.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Renuvion and Safety: Understanding the FDA Approvals &amp; Myths"}]},{"@type":"WebSite","@id":"https:\/\/www.lyosmd.com\/blog\/#website","url":"https:\/\/www.lyosmd.com\/blog\/","name":"Dr. Andrew Lyos - Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lyosmd.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.lyosmd.com\/blog\/#\/schema\/person\/401fd8985cd2c1a9400ff99d1eb3e606","name":"studio3","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lyosmd.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9c5ffeafe60563b0bf588751b0c77210cd130d78326974eaf8107bd04097d202?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9c5ffeafe60563b0bf588751b0c77210cd130d78326974eaf8107bd04097d202?s=96&d=mm&r=g","caption":"studio3"},"url":"https:\/\/www.lyosmd.com\/blog\/author\/studio3\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/posts\/6065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/comments?post=6065"}],"version-history":[{"count":1,"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/posts\/6065\/revisions"}],"predecessor-version":[{"id":6066,"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/posts\/6065\/revisions\/6066"}],"wp:attachment":[{"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/media?parent=6065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/categories?post=6065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lyosmd.com\/blog\/wp-json\/wp\/v2\/tags?post=6065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}